WuXi Biologics
Offering End-to-End Solutions
WuXi Vaccines and Delonix Bioworks Achieve Strategic Partnership to Accelerate Global Application of Innovative OMV Vaccine Technology
Suzhou, April 21, 2025 – WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), and Delonix Bioworks, a global pioneer in innovative bacterial vaccine development, today announced a strategic partnership. Through the...Accelerating Recombinant Protein Vaccine Development
Accelerating Recombinant Protein Vaccine Development WuXi Vaccines describes technologies that hasten the progress from vaccine discovery to commercialization By Jason He, PhD January 10, 2024 More automated processes can give scientists access to high-throughput...WuXi Vaccines Named Best Contract Manufacturing Organization at ViE Awards 2024
SHANGHAI, April 8, 2024 – WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), announced it was named “Best Contract Manufacturing Organization” at the 17th annual Vaccine Industry Excellence Awards...WuXi Vaccines and Delonix Bioworks Announce Agreement to Accelerate Development and Manufacturing of Innovative Bacterial Vaccines
Suzhou, China, January 25, 2024 – WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), and Delonix Bioworks Ltd. (“Delonix”), a world-leading biotech company dedicated to the design and engineering of microbes for...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?